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Abstract 
Lung transplant is a treatment modality for patients with end stage lung disease. 
Bronchiolitis obliterans syndrome (BOS) is the number one cause of morbidity and 
mortality in patients the first year after lung transplant. There are many risk factors which 
have been identified to increase the risk of BOS including acute rejection, lymphocytic 
bronchitis, medication non-compliance, bacterial or viral infections, older donor age, 
extended ischemic time, donor antigen-specific reactivity, human leukocyte antigen 
(HLA) mismatch, underlying disease and gastroesophageal reflux disease (GERD). 
Advanced practice nurses can help in the primary prevention of BOS through the 
assessment and treatment of pre-transplant patients with GERD. A descriptive study 
using retrospective chart reviews of lung transplant recipients was conducted to evaluate 
the relationship between pre-transplant GERD and post-transplant BOS. The incidence of 
pre-transplant GERD was 39%. The incidence ofBOS at year one was 17% and at year 
two was 32%. There was not a significant relationship between pre-transplant GERD and 
post-transplant BOS. 
CHAPTER ONE 
Introduction 
Over 1700 transplants are performed world wide every year for select end stage 
lung diseases (Trulock et al., 2005). The most common diseases for which lung transplant 
is an indication are chronic obstructive lung disease, idiopathic pulmonary fibrosis (IPF), 
cystic fibrosis (CF), pulmonary hypertension, and Eisenmenger syndromes. Less 
common indications for lung transplant include bronchiectasis, sarcoidosis, and 
lymphangioleiomyomatosis (LAM) and pulmonary Langerhans cell histiocytosis 
(Trulock et al., 2005). 
One possible complication of lung transplant is chronic rejection, more commonly 
known as bronchiolitis obliterans syndrome (BOS). BOS is the most common cause of 
death after the first year post-transplant (Trulock et al., 2005). The cause ofBOS is 
unclear and controversial. Gastroesophageal reflux disease (GERD) is a comorbid 
condition in end stage lung disease and is a suspected risk factor for the development of 
BOS in lung transplant recipients (D'Ovidio & Keshavjee, 2006; Trulock et al., 2005). 
Although there have been multiple studies that have looked at the role of GERD and 
allograft dysfunction, further research examining GERD and its association with BOS is 
warranted to optimize prevention and treatment options. 
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Conceptual Framework 
Margaret Newman's model of health as expanding consciousness (HEC) is the 
theoretical framework used to guide this research. The model has three main concepts: 
health, pattern and consciousness. Newman defines health as the expansion of 
consciousness and is inclusive of both disease and nondisease (Newman, 2000). Health is 
viewed as the recognition of the evolving pattern of human-environment interaction. 
Newman asserts that disease is not a negative, as one in the medical field may presume, 
but that "health includes disease and disease includes health" (Newman, 2000, p. 6). With 
this in mind, the focus of the nurse should be placed on facilitating the individual's 
recognition of their own expanding consciousness and on recognition of patterns rather 
than simple identification of symptoms. 
Patterns are the individual differences that make a person who they are. Every 
individual is different. It is important for individuals to recognize that their disease is not 
a separate entity, but rather to identify it as their own particular pattern. This will allow 
them to understand themselves and how they fit in the larger pattern of the environment 
(Newman, 2000). 
"Consciousness is defined as the informational capacity of the system: the ability of 
the system to interact with its environment" (Newman, 2000, p. 33). Every individual is 
unique and has his or her own pattern that is within the system which is described by 
Newman. This individual then has to interact and adapt with the environment that is 
around them which is the act of finding his or her consciousness. 
There are three sub concepts that define consciousness: time, movement and 
space. Time and space are not specifically defined within Margaret Newman's 
model. Newman refers to time as it is relevant to the individual person; this was 
regarded as private time. Coordinated and shared time referred to the time that 
was spent with family (Newman, 2000). When an individual's space is increased 
or decreased then his or her time is decreased or increased respectively. With time 
the individual is in tune with their past, present and future. With this the 
individual is able to work within their environment with whatever limitations he 
or she may or may not perceive. Movement is defined as the events that happen in 
individuals' lives that may change both their reality and their pattern. 
Individuals with end stage lung disease live in a chronic disease state that is 
usually terminal. In this chronic disease state the individual has periods of 
relatively stable health followed by an exacerbation of the chron!c disease. This 
establishes the pattern that identifies and is specific to that individual (Newman, 
2000). Over time the individual's pattern changes depending on the stage of the 
disease. For individuals who undergo transplantation, their pattern changes once 
again. The individual's consciousness is expanded by learning how to adapt in the 
environment as the pattern continuously changes. 
In this expansion of consciousness, individuals who are lung transplant 
recipients must make life changes in order to protect themselves from injury to 
their transplanted organ. They are in constant movement to become aware of 
themselves in order to recognize when they may be facing a change in health. 
Lung transplant recipients are always at risk for decline. It is important for them 
to be aware of their pattern and to report their symptoms of health to their health 
care provider so that if there is a problem the provider may intervene. 
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One pattern that may evolve for lung transplant recipients is BOS. Patients 
must be educated and aware of the pattern that this disease may portray so that 
they can inform their provider in order to potentially reverse or halt the 
progression of the syndrome. Recipients who are expanding their consciousness 
and always in tune with their pattern and their environment are taking 
responsibility for themselves and the organ that they received. 
Purpose 
The purpose of this study was to examine the relationship between pre-
transplant GERD and the development of post-transplant BOS among lung 
transplant recipients. 
Research Questions 
There were four questions for this study. Among lung transplant recipients: 
1. What is the incidence of pre-transplant GERD? 
2. What is the incidence of post-transplant BOS? 
3. What is the relationship between pre-transplant GERD and post-
transplant BOS? 
4. What are the sensitivity and specificity of pre-transplant GERD as a 
predictor of post-transplant BOS? 
Definition ofTerms 
Lung transplant. A surgical procedure to transfer a lung from a person who 
has died to another living person who has end stage lung disease. 
Gastroesophageal reflux disease. GERD is a condition where there is 
repeated backward movement of stomach contents into the esophagus causing 
damage to the esophageal tissues (McCance & Huether, 2006). 
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Bronchiolitis obliterans syndrome. BOS is chronic rejection of the 
transplanted graft evidenced by persistent airflow obstruction (Trulock, Patterson, 
& Cooper, 2007). 
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CHAPTER TWO 
Literature Review 
This chapter provides a general overview of lung transplant, including history, 
processes for organ procurement, indications for lung transplant, postoperative 
complications and prognosis. This will be followed by a discussion of bronchiolitis 
obliterans (BOS), gastroesophageal reflux disease (GERD), including etiology, 
symptomology, treatment and prognosis. Finally, a discussion of the suspected role of 
GERD in the development of BOS after lung transplant will be presented. 
Lung Transplant 
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Lung transplant has become an accepted viable treatment for end stage lung 
disease, providing an increased quality of life and survival benefit (Trulock et al., 2005). 
In 1963, the first human lung transplant was performed with very poor results 
(Blumenstock & Lewis, 1993). Lung transplantation was not attempted again unti11981, 
when a combination heart-lung transplant was performed (Reitz et al., 1982). In 1983, a 
single lung transplant succeeded due to improvements in surgical techniques and 
immunosuppressive agents (Toronto Lung Transplant Group, 1986). In 1986, a double 
lung transplant was performed at the University of Toronto (Cooper, Patterson, 
Grossman, & Maurer, 1989). During this time the pharmacologic agent cyclosporine was 
introduced as an immunosuppressant which enhanced the success of the transplants in the 
1980's. 
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Christie et al. (2008) describe the survival of lung transplant patients from January 
1994 through June 2006. Survival rate for lung transplant recipients at one year was 78%, 
at five years 51% and at ten years 28%. Causes of death post lung transplant included 
acute or chronic rejection, malignancy, infection, graft failure, cardiovascular events and 
technical complications. Chronic rejection, more commonly known as BOS, along with 
non- CMV infection and graft failure are the most common reason for death after the first 
year post lung transplant (Christie et al., 2008). BOS clinically evolves as a progressive 
loss of airflow due to the obstruction of the smaller airways. The course of the disease 
can be either rapid or slow. The experience is different for each patient. 
The number of patients who are currently on the waiting list for transplant exceeds 
the number of donors that are available. At the end of2005 there were 3,170 patients 
listed and waiting for lung transplant with only 1,287 available living and deceased 
donors (Scientific Registry of Transplant Recipients, n.d.). The average wait time for 
patients who are listed to be transplanted according to United Network of Organ Sharing 
(UNOS) is 588 days (Organ Procurement and Transplantation Network, n.d.). 
Organ procurement. Due to the shortage of organs, the identification process for 
the recipients of organs is very selective. Organ allocation in the United States is 
governed under the United States Department of Health and Human Services (Rudow, 
Ohler, & Shafer, 2006). The Organ Procurement and Transplantation Network (OPTN) 
was established by the United States Congress under the National Organ Transplant Act 
(NOTA) of 1984. The purpose of the OPTN was to establish and maintain a national list 
of individuals who need organs through a national system in a database with established 
medical criteria to match organs to the individuals on the list. The OPTN is dedicated to 
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increasing and ensuring the effectiveness, efficiency, and equity of the organ allocation 
system and to increasing the number of donated organs that are utilized in transplantation 
(Rudow et al., 2006). 
In 1986, UNOS was awarded the contract to establish and operate the OPTN. 
Under this contract UNOS developed a system that is used for the collection, storage, 
analysis and publication of all data pertaining to transplant and to provide guidance to 
anyone concerned with transplantation and information to increase donor awareness 
(Rudow et al., 2006). UNOS uses a defined lung allocation system (LAS) for the 
distribution of organs to those candidates who are on the waiting list. This system was put 
in place to clarify the order that lung offers are made to the transplant candidates. The 
candidates are assigned a LAS that is determined by each candidate's medical 
information criteria. The score allows the sickest candidates with the highest chance of 
survival the best opportunity of getting a transplant (Rudow et al., 2006). Organ 
procurement organizations (OPOs) operate under UNOS and are responsible for the 
recovery of organs and allocation of those organs in their geographic regions in 
accordance to the UNOS guidelines. 
Indications for lung transplant. The common lung diseases that are indications for 
lung transplant include chronic obstructive pulmonary disease (COPD), alpha- I 
antitrypsin deficiency, idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), 
idiopathic pulmonary hypertension (IP AH) and Eisenmenger syndrome (Trulock, 2006b ). 
Lung transplant is considered for patients with end stage lung disease when they are 
failing medical treatment or an effective medical treatment is nonexistent (Orens et al., 
2006). Candidates for lung transplant referred to a transplant center for evaluation is 
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dependent on many factors including the patient's quality oflife, the patient's desire for 
information regarding lung transplant and the referring physician's clinical decision 
regarding the patient's survival. Ideally listing of a lung transplant patient should take 
place when the patient with end stage lung disease's life expectancy is considerably 
reduced to where it may be affecting quality of life and activities of daily living but does 
not exceed the waiting time for donor lungs (Orens et al., 2006). To review as it was 
discussed earlier the average wait time for some one who is listed for lung transplant 
according to UNOS is 588 days. (Organ Procurement and Transplantation Network, n.d.). 
The general guidelines for selection of recipients for lung transplant have been 
outlined by the International Society of Heart and Lung Transplantation (ISHLT) (see 
Table 2.1 ). Upon completion of a comprehensive transplant evaluation and after all 
potential contraindications have been ruled out the patient is placed on the waiting list. 
Postoperative course and potential complications. Postoperatively, the patient 
spends 24 to 48 hours in the intensive care. Upon arrival to the intensive care, the patient 
has an endotracheal tube and is placed on mechanical ventilation. Bronchoscopy is 
performed via the endotracheal tube to assess the anastomosis site and obtain 
bronchoalveolar lavage for cultures. The patient is usually extubated within 24 hours 
after transplantation to avoid complications. Hospitalization usually lasts five to fourteen 
days. Patients are encouraged to start ambulating within 24 hours post transplant. Patients 
are discharged from the hospital after chest tubes are removed and they are able to 
resume oral intake. 
Table 2.1. 
Selection Criteria for Lung Transplant 
Age Limits 
Single lung transplant: 65 years old 
Double Lung transplant: 60 years old 
Absolute Contraindications 
Malignancy in the last two years 
Untreatable Advanced organ dysfunction 
Untreatable Chronic extrapulmonary infection 
Significant chest wall or spinal deformity 
Noncompliance 
Untreatable Psychiatric or psychological condition 
Substance addiction < six months 
Relative Contraindications 
Age greater than 65 
Critical clinical condition 
Limited functional status 
Colonization with resistant bacteria, fungus or mycobacterium 
Body mass index > 3 0 
Severe osteoporosis 
Mechanical ventilation 
Other comorbidities 
Adapted from "International guidelines for the selection of lung transplant candidates: 
2006 update - a consensus report from the pulmonary scientific council of the 
international society for heart and lung transplantation," by J.B. Orens et al., 2006, The 
Journal of Heart and Lung Transplantation, 25(7), pp. 746-747. 
Early in the postoperative phase, patients may experience complications with 
reperfusion injury, primary graft failure, and cardiac arrythmias (Trulock et al., 2007). 
Reperfusion injury occurs from alveolar damage and increased vascular permeability, 
which can happen within hours or up to days following the transplant surgery. Primary 
graft failure is similar to acute lung injury that occurs shortly after the lung is 
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transplanted and may happen because of problems with the donor lung that occurred prior 
to transplant. These problems include aspiration, contusion during removal or transport, 
or inadequate lung preservation. Cardiac arrhythmias are common after lung transplant 
and are usually atrial in nature because of the proximity of the atrial cuff to the 
anastamosis site, the trauma and inflammation can impede electric conduction. 
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Other complications may occur in the first days to weeks after surgery. Vascular 
complications that may occur include pulmonary artery stenosis and pulmonary venous 
obstruction increased pulmonary pressures or pulmonary vein thrombosis. Airway 
complications include bronchial dehiscence or stenosis of the anastamosis. Pleural 
complications will usually occur in the first month post lung transplant and are usually 
caused by infection, poor pleural drainage, or rejection. Infection is common after lung 
transplant and is related to the surgery itself and to ventilator dependence. Infection may 
also come from the donor lung (Trulock, 2006a). 
Long term consequences of lung transplant are the result of physiologic changes 
that occur because of the pulmonary denervation that happens during surgery. The 
patient's ability to control breathing is changed due to the cutting of the afferent and 
efferent nerves to the lung during organ retrieval. Reinnervation does not occur in the 
post transplant period. Patients also experience impairment of the cough reflex and 
mucociliary clearance because the afferent limb of the cough reflex is severed and does 
not regenerate. The patient continues to have the ability to cough by other means such as 
stimulation from the native lung or from sites in the respiratory tract that are proximal to 
the airway anastamosis (Trulock, 2003). 
In the post transplant period the patients are followed periodically for a lifetime to 
monitor for acute and chronic rejection, infection, and immunosuppression levels. 
Immunosuppressive medications are indicated to prevent organ rejection immediately 
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post transplant. These medications are implemented immediately prior to or immediately 
after surgery. Induction therapy is the use of immunosuppressive medications such as 
cytolytic agent, monoclonal antibodies, and humanized monocolonal interleukin 2 
receptor antagonists in the first five to seven days after transplantation. Common 
medications that are used in the post transplant period include calcineurin inhibitors such 
as cyclosporine or tacrolimus, azathioprine or mycophenolate mofetil, and 
corticosteroids. Labs are monitored at regular intervals to determine therapeutic levels 
and adjust medications as needed (Trulock & Mandel, 2006). 
Infection. Patients in the post transplant period are more prone to infections due to 
the immunosuppressive medications needed to avoid rejection in the post-transplant 
period, impaired cough reflex, and impaired mucociliary clearance. The pathophysiology 
of infection may include the presence of acute inflammatory cells, alveolar inflammation, 
viral inclusions, and infectious pathogens identified by special stains (Reilly, 2005). 
Some infections that may occur in post-transplant patients include bacterial pneumonia 
(Pseudomonas species, Enterobacter, Staphylococcus aureus, Enterococcus species, and 
Hemophilus influenzae ), viral infections (cytomegalovirus, herpes simplex virus, 
respiratory syncytial virus, and influenza), and fungal infections (candida and 
aspergillus). 
Acute transplant rejection. Acute rejection is a celluar mediated immune response 
that usually occurs frequently in the first few months after lung transplant and decreases 
over time. Approximately 40% of patients will develop acute rejection in the first month 
after transplant (Trulock et al., 2007). 
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Patients with acute rejection may have no symptoms at all or may experience low 
grade fever, shortness of breath, nonproductive cough, and drop in oxygen saturation or 
drop in spirometry. The pathology representing acute rejection includes endothelial 
inflammation and lymphocyte infiltration in the alveolar walls and the airways. Acute 
rejection is diagnosed by clinical and diagnostic tools such as bronchoscopy with biopsies 
and bronchoalveolar lavage to rule out rejection versus infection. Acute rejection is 
graded by guidelines provided by the ISHL T (See Table 2.2). Acute rejection is graded 
by the pathology of the lung tissue and the degree of airway inflammation with 
lymphocytic bronchitis. Rejection versus infection can be a difficult diagnosis to make 
because both cause inflammation of the lung parenchyma (Stewart et al., 2007). Formal 
measurement of lung function with pulmonary function testing can be performed to 
assess for acute rejection. Chest x-ray can be used to rule out infiltrates or pleural 
effusion which may represent acute rejection. 
Treatment for acute rejection depends on several factors including, severity of the 
rejection, clinical symptoms of the patient, and the presence of infection. In practice 
grade three and grade four rejections are always treated. The treatment of grade one and 
grade two rejection is more variable depending on the factors mentioned above. Steroid 
boluses for three days are used to treat acute rejection. Spirometry or follow up 
transbronchial biopsies may be performed to follow up the resolution of acute rejection 
(Reilly, 2006). 
Table 2.2 Classification and Grading of Pulmonary Allograft Rejection 
A: Acute Rejection 
Grade 0 None 
Grade 1 Minimal 
Grade 2 Mild 
Grade 3 Moderate 
Grade 4 Severe 
B: Airway Inflammation 
Grade 0 None 
Grade 1R* 
Grade 2R* 
Grade X 
Low grade 
High grade 
Ungradable 
C: Chronic airway rejection- obliterative bronchiolitis 
0 Absent 
1 Present 
D: Chronic vascular rejection- accelerated graft vascular sclerosis 
* Revised grade to avoid confusion with 1996 scheme 
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From "Revision of the 1996 working formulation for standardization of nomenclature in 
the diagnosis oflung rejection," by S. Stewart et al., 2007, The Journal of Heart and 
Lung Transplantation, 26(12), p. 1230. 
Bronchiolitis Obliterans Syndrome 
BOS, chronic transplant rejection, is the primary cause of morbidity and mortality 
following the first year of lung transplantation can manifest itself in two classifications: 
chronic airway rejection or chronic vascular rejection (Reilly, 2006). Chronic airway 
rejection, the more common manifestation results in occlusion of the airways. Chronic 
vascular rejection is caused by atherosclerosis of the pulmonary vasculature, resulting in 
BOS. BOS can have a very unpredictable clinical course. Some individuals have a slow 
progression with gradual loss of lung function while others have a rapid progression into 
respiratory failure (Estenne et al., 2002). 
Pathophysiology. BOS develops with submucosal lymphocytic inflammation 
resulting in the disruption of the epithelium in the small airways. Following the 
inflammation of the small airways, there is a fibromyxoid granulation which ultimately 
causes partial or complete occlusion of the airway (Reilly, 2006). 
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ISHLT has defined three categories of risk factors for BOS: probable, potential and 
hypothetical according to reliability and quality of evidence in the research available 
(Estenne et al., 2002). Probable risk factors are acute rejection, lymphocytic bronchitis, 
medication non-compliance and cytomegalovirus (CMV) infection. Potential risk factors 
include organizing pneumonia, bacterial, fungal and non-CMV viral infection, older 
donor age, longer ischemic time, and donor antigen-specific reactivity. Hypothetical risk 
factors include genotype of the recipient for certain cytokine gene polymorphisms, 
human leukocyte antigen (HLA) mismatch, underlying disease, and GERD with 
aspiration. 
Nonimmunologically mediated risk factors that may contribute to the development 
ofBOS include acute rejection, lymphocytic bronchitis, ischemic injury, GERD and 
bacterial, viral, or fungal infections. The most common risk factor for BOS is acute 
rejection. Multiple episodes of rejection may increase the risk of developing BOS. 
Lymphocytic bronchitis, or inflammation of the tissue in the airways from either acute 
rejection or infection may also predispose individuals to BOS. Some experts hypothesize 
that ischemic injury after transplantation may play a role in the development ofBOS. 
GERD has been identified to be a predisposing risk factor ofBOS. Respiratory infections 
from bacteria, virus, or fungus have been established as a cause of BOS (Sharples, 
McNeil, Stewart, & Wallwork, 2002). 
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BOS continues to be an ongoing challenge in lung transplantion. BOS may occur 
due to many different factors and much research needs to be done in the future regarding 
the multiple risk factors. The mmiality and morbidity of lung transplant recipients is 
significantly affected by BOS. The development ofBOS by five years after lung 
transplant is a significant complication. Between Aprill994 and June 2004, 43% oflung 
transplant patients had developed BOS (Trulock et al., 2005). BOS continues to be the 
number one cause of death in this population one year or greater post transplant. 
Diagnosis. BOS is diagnosed either by clinical suspicion after all other causes of 
functional decline are eliminated or by histological confirmation by transbronchial biopsy 
or open lung biopsy. The ISHL T has defined the diagnostic criteria for BOS based on 
pulmonary function using forced expiratory volume in one second (FEV 1) (Estenne et al., 
2002). The baseline FEV1 is the average ofthe two highest measurements obtained at 
least three weeks apart post lung transplant (Estenne et al., 2002). The percent of decline 
in the individual's FEV1 post transplant can then be calculated. The mid-expiratory flow 
rate (FEF25_75) is a pulmonary function measurement that may show decline before the 
FEV 1 the ISHL T uses both measurements as defining factors in the early stages of BOS 
(Estenne et al., 2002) (see Table 2.3). 
Treatment. There is not a single proven treatment for BOS. Many pharmacologic 
agents have been used in an effort to stabilize the drop in FEV 1 in lung transplant 
patients. Some of these treatments have been effective in halting the progression ofBOS. 
These include high dose steroids, azithromycin, cytolitic therapy, a change in calcinurin 
inhibitor, total lymphoid irradiation, plasmapheresis, photopheresis and retransplantation 
Table 2.3 
Bronchiolitis Obliterans Syndrome (BOS) Classification 
BOS Grade BOS Criteria 
BOS 0 FEV1 > 90% ofbaseline and FEF 25-75 > 75% ofbaseline 
BOS 0-p FEV1 81% to 90% of the baseline and/or FEF 25-75 :S 75 of baseline 
BOS 1 FEV 1 66% to 80% of baseline 
BOS 2 FEV1 51% to 65% ofbaseline 
BOS 3 FEV 1 50% or less of baseline 
Note: FEV 1 forced expiratory volume in one second 
FEF25-75 mid-expiratory flow rate 
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From "Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria," by 
M. Estenne et al., 2002, The Journal of Heart and Lung Transplantation, 21(3), p. 
299. 
(Trulock & Mandel, 2006). The outcomes for these treatments have not been promising. 
The best treatment for BOS continues to be aggressive primary prevention. 
Gastroesophageal Reflux Disease 
GERD is a condition that in which there are symptoms associated with reflux of 
gastric contents into the esophagus (Devault & Castell, 2005). GERD affects five in 
every thousand persons in the United States each year (Kahrilas, 2006). 
Pathophysiology. The lower esophageal sphincter (LES) is responsible for keeping 
acid out of the esophagus by maintaining a high pressure region that does not allow for 
gastric contents to enter the esophagus (McCance & Huether, 2006). Reflux occurs when 
the pressure between the LES and the stomach is decreased due to relaxation or weakness 
ofthe sphincter. The presence and severity of reflux is influenced by factors that increase 
abdominal pressure, such as vomiting, coughing, lifting and bending. Other conditions 
that increase the incidence of esophageal reflux include hiatal hernia and delayed gastric 
emptying (McCance & Huether, 2006). 
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The risks of esophageal reflux are inflammation to the esophageal wall which 
increases capillary permeability resulting in edema, fragile tissue, erosions and 
ulcerations. The severity of reflux depends on the gastric contents, the length of exposure 
the contents have with the esophagus, and the epithelial resistance to acid exposure 
(McCance & Huether, 2006). 
Symptoms. Individuals with a diagnosis of GERD have symptoms of heartburn, 
regurgitation, upper abdominal pain within one hour of eating and dysphagia. These 
symptoms usually worsen when the individual is in a supine position or if the 
intrabdominal pressure increases. The symptoms are relieved by the use of antacids. 
Other symptoms of GERD include chest pain, hypersalivation, chronic cough, wheezing, 
sore throat, hoarseness, eructation, and nausea (Kahrilas, 2006). 
Diagnosis. GERD is usually diagnosed based on the patient's history. Diagnostic 
testing such as endoscopy should be considered in individuals with complicated disease 
such as patients at risk for Barrett's esophagus, a complication of GERD that is 
predisposed to esophageal adenocarcinoma (Devault & Castell, 2005). All patients with a 
history of GERD for five years should undergo endoscopy to evaluate for Barrett's 
esophagus. Other diagnostic tests include ambulatory esophageal pH monitoring, 
esophageal manometry, Berstein test, and barium swallow (Kahrilas, 2006). 
Treatment. Treatment for GERD includes lifestyle modifications, 
pharmacotherapy, and surgery (Kahrilas, 2006). Lifestyle modifications include elevating 
the head of the bed, decreasing fat intake, abstinence from smoking, and avoiding a 
supine position three hours after eating. Dietary modifications include avoidance of foods 
known to lower the pressure of the LES, such as chocolate, alcohol, peppermint, and 
coffee (Devault & Castell, 2005). 
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Medications used for the treatment of GERD include over the counter antacids and 
acid suppressants, histamine 2-receptor blockers, proton pump inhibitors and promotility 
agents. Most individuals who experience intermittent symptoms of GERD respond well 
to over-the-counter antacids such as calcium carbonate, aluminum hydroxide, and 
simethicone. Histamine-2 receptor blockers such as cimetidine, famotidine, nizatidine, 
and ranitidine or proton pump inhibitors such as esomeprazole, lansoprazole, omeprazole, 
and pantoprazole are used for individuals who have continuous symptoms. Although both 
classifications of drugs act to suppress acid production, the proton pump inhibitors are 
more effective in patients with severe GERD (Goyal, 2007). Promotility agents such as 
metoclopramide, may be used in conjunction with histamine 2-receptor blockers or 
proton pump inhibitors, but not as monotherapy (D'Ovidio et al., 2005). Promotility 
agents increase the motility of the upper gastrointestinal tract. 
Antireflux surgery can be used as a maintenance treatment for individuals with 
severe gastroesophageal reflux disease. The purpose of the surgery is to restore the LES. 
This can be done by Nissen fundoplication, Belsey Mark IV, and Hill repair. The Nissen 
fundoplication can be preformed either surgically or laparoscopically, where they 
surgically place a wrap around the LES to control reflux. The Belsey Mark IV is a partial 
fundoplication which allows mobilization of the esophagus. The Hill repair involves the 
overlapping of the gastric curve around the esophagus with attachment of the complex to 
the medican arcuate ligament, closing the diaphragm (Sampliner, 2006). This treatment 
option remains controversial for its long term efficacy (Devault & Castell, 2005). 
Role of Gastroesophageal Reflux in Lung Transplant and Bronchiolitis Obliterans 
GERD is a known comorbidity in end stage lung disease, occurring in as many as 
63% of patients awaiting lung transplantation (D'Ovidio et al., 2005). GERD is also 
suspected to be a nonimmunologically mediated risk factor that causes both allograft 
dysfunction and BOS in lung transplant recipients (D'Ovidio & Keshavjee, 2006). 
There are several theories for worsening GERD post lung transplant. 
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Immunosuppressive agents, including calcineurin inhibitors and prednisone, are 
administered to the transplant recipients to prevent rejection. These medications also 
delay gastric emptying and increase the incidence of GERD by prolonging the time that 
the food is in the stomach to potentially reflux into the esophagus (D'Ovidio & 
Keshavjee, 2006). Iatrogenic vagal nerve injury during lung transplantation may occur. 
Such an injury causes diaphragm paralysis and the denervation of the lungs that occurs 
with the transplantation produces suboptimal cough reflex and mucociliary clearance 
(Trulock, 2003). With these impaired lung defenses, the lungs may not be able to 
appropriately eliminate offending gastric contents that may get aspirated (D'Ovidio & 
Keshavjee, 2006). 
It is known that the severity of GERD worsens after lung transplant surgery 
(Young, Hadjiliadis, Davis, & Palmer, 2003). The suspicions of the relationship between 
GERD and BOS are beginning to be demonstrated empirically. In two animal studies of 
lung transplant in rats it was found that lungs exposed to aspiration demonstrated severe 
rejection with increased monocyte infiltration and fibrosis (Hartwig et al., 2006; Li et al., 
2008). A study of lung transplants in miniature swine was designed by aspirating gastric 
contents via a gastrostomy tube to replicate reflux. The results of the study concluded that 
acid reflux enhances an indirect alloresponse, revealing that GERD may be injurious to 
the transplanted lung (Meltzer et al., 2008). 
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In studies of humans, the incidence of GERD in patients post lung transplant is 
70% to 90% (Benden et al., 2005; Hadjiliadis et al., 2003). Several studies have 
measured bile acid in bronchoalveolar lavage fluids and found that exposure to bile acids 
in the transplant lung shortened the time to diagnosis ofBOS (D'Ovidio et al., 2006; 
D'Ovidio et al., 2005; Blondeau et al., 2009). Blondeau et al. (2008) conducted a study 
that evaluated pepsin and bile acid and their association with BOS. They concluded that 
pepsin was a general marker whereas bile acid was a more specific marker that may lead 
to the development ofBOS. They also examined treatment with proton pump inhibitors 
and found that they did not stop nonacid reflux and gastric aspiration. 
There is evidence that fundoplication surgery may be useful in the prevention of 
early allograft dysfunction and the development ofBOS (Hartwig, Appel, & Davis, 
2005). Other studies have found that fundoplication can improve the outcome of patients 
who are undergoing or who have undergone lung transplantation. A single patient case 
study described dramatic improvement in both reflux symptoms and pulmonary function 
after fundoplication surgery (Palmer et al., 2000). Cantu et al. (2004) studied 127 lung 
transplant patients and reported that 76% had abnormal esophageal acid evaluated by pH 
probe. Fourteen of these patients met the diagnosis ofBOS and did undergo 
fundoplication. They were again evaluated after the fundoplication and their BOS 
improved or ceased. This suggested that GERD did contribute to the development of 
BOS. Davis et al. (2003) found similar results in their study of 128 lung transplant 
patients and reported that 73% had abnormal esophageal acid evaluated by pH probe. 
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Forty-three patients underwent fundoplication and 26 of these patients met the diagnosis 
ofBOS. The 26 patients were again evaluated after the fundoplication and their BOS 
improved or ceased. Additional studies have been conducted to disclose the same 
conclusion that fundoplication can be performed safely in selected lung transplant 
candidates in order to improve or abate reflux symptoms and ultimately improve their 
lung function (Lau et al., 2002; O'Halloran et al., 2004). Other studies have shown that 
performing fundoplication in patients with end stage lung disease prior to lung 
transplantation can also be done safely and successfully with positive outcomes. (Gasper 
et al., 2008; Linden et al., 2006). 
Summary 
Although lung transplantation increases the quality of life for many patients with 
end stage lung disease, BOS continues to be a devastating complication for lung 
transplant recipients one year after transplantation. It has been suggested that GERD can 
be a predisposing factor for the development ofBOS. Multiple studies of lung transplant 
patients in this area have supported the concept, but it still remains to be fully understood 
and accepted. Continued study in this area is warranted as lung transplant is an evolving 
treatment for end stage lung disease in the last two decades. 
CHAPTER THREE 
Methodology 
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This Level II correlational study utilized a retrospective chart review to determine 
the relationship between pre-transplant GERD and the development of post-transplant 
BOS among lung transplant recipients. 
Sample and Setting 
The study population consisted of the medical records of all patients who received 
a lung transplant at a major medical research and teaching facility in the southeastern 
United States between June 2001 to October 2005. This medical facility is a 224-bed 
institution with an average of 30 lung transplants performed each year. A power analysis 
revealed that the sample size needed to determine a significant relationship with a= .05 
in a two tailed test, a medium effects size and a power= of .80 would be 88 subjects. 
Data Collection 
The data were collected through a retrospective chart review. Medical records of 
all patients undergoing lung transplant between June 2001 and October 2005 were 
reviewed and examined. The data were extracted regarding demographic and study 
variables (see Appendix for data collection tool). 
The diagnosis ofGERD was assessed by (a) history, (b) esophagogastro-
duodenoscopy with or without Bravo capsule, (c) pH probe, (d) barium swallow or (e) 
documented use of proton pump inhibitors. The diagnosis of BOS was be assessed by the 
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percent drop of the FEV1 post transplant, and the number of months post-transplant that 
the BOS started to develop. 
Protection of Human Subjects 
Institutional Review Board (IRB) approval Expedited Status to conduct the study 
was obtained from the University of North Florida IRB and from the IRB of the facility 
where data were collected. The principal investigator was the only person with direct 
access to the medical records. No personal identifying information was collected and 
there was no direct interaction with patients 
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CHAPTER FOUR 
Results 
The data were entered into a spreadsheet and checked for accuracy. Data analysis 
was accomplished using Microsoft Excel 2003® and SPSS 16.1 for Windows®. This 
chapter presents sample characteristics and a description of the results for each research 
question. 
Sample Characteristics 
One-hundred patients met the inclusion criteria. There were a total of 102 
transplants, with 2 patients who were re-transplanted during the study period. The 
patients were between 16 and 74 years-of-age (M= 55.99, SD = 12.91) with a median of 
59 years-of-age. Further characteristics of the sample may be found in Table 4.1. 
The survival of the lung transplant patients was from 0 to 91 months (M = 41.76 
Months; SD=25.69 months) with a median of 44 months. The survival rate at one year 
was 84%, two years 74% and three years 63%. 
Research Question One 
The first research question was: what is the incidence of pre-transplant GERD? Of 
the 100 patients whose records were reviewed, 39 had pre-transplant GERD. Eighteen 
(46.15%) were on medical treatment and also had symptoms which lead to a clinical 
diagnosis ofGERD. Fourteen (35.90%) were on medical treatment without clinical 
symptoms but in the presence of risk factors for GERD, 3 (7.69%) were diagnosed by 
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Table 4.1 
Patient Demographics (n=IOO patients) 
Characteristics N 
Gender 
Male 54 
Female 46 
Blood T.n~e 
0 43 
A 39 
B 16 
AB 2 
Diagnosis 
Idiopathic pulmonary fibrosis 44 
COPD/Emphysema 37 
Pulmonary hypertension 5 
Cystic fibrosis 3 
Eisenmenger's Syndrome 3 
Lymphangioleiomyomatosis 3 
Re-transplant 2 
Bronchiectasis 2 
Other* 3 
* Other diagnoses leading to the need for lung transplant were silicosis, bronchoalveolar 
cell carcinoma, and Shwachman-Diamond syndrome with one case in each category. 
barium swallow and pH probe, 2 (5.13%) by EGD, and 1 (2.56%) by bravo capsule and 
EGD. All of these patients were also on medical treatments because of clinical 
symptoms. One (2.56%) patient had already had a fundoplication for previous diagnosis 
ofGERD. 
The incidence of pre-transplant GERD varied by gender. Twenty-four (61.53%) of 
the individuals with GERD were male and 15 (38.46%) female. 
Research Question Two 
The second research question was: what is the incidence of post-transplant BOS in 
lung transplant recipients? Only 84 of the 100 patients were able to be evaluated for first 
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year post-transplant information because 16 patients did not survive the first year. 
Fourteen (16.67%) of the 84 patients developed BOS within one year after transplant: 8 
(57.14%) with BOS grade 1, 2 (14.29%) with BOS grade 2, an~ 4 (28.57%) with BOS 
grade 3. An additional10 patients did not survive the second year, so only 74 patients 
were able to be evaluated for second year post-transplant information. Twenty four 
(32.43%) of the 74 patients developed BOS within two years after transplant: 12 (50%) 
with BOS grade 1, 3 (12.5%) with BOS grade 2, and 9 (37.5%) with BOS grade 3. (See 
Figure 4.1) 
Survival - 805 
100 Lung Transplant Recipients 
1 month 12months 24months 
Figure 4.1 
Survival Rate and Incidence of Post-transplant BOS 
The incidence of post-transplant BOS varied by gender in the first year, but not in 
the second. Nine (64.28%) of the individuals with BOS at 1 year post-transplant were 
female and 5 (35.71 %) were male. Thirteen (54.16%) of the individuals with BOS at 2 
years post-transplant were female and 11 (45.83%) were male. 
Research Question Three 
The third research question was: What is the relationship between pre-transplant 
GERD and post-transplant BOS in lung transplant recipients? Fourteen out of the 39 
individuals (35.89%) with pre-transplant GERD developed post-transplant BOS by one 
year post-transplant. At two years post-transplant, 24 out of 39 individuals (61.53%) 
developed post-transplant BOS. There was not a significant relationship between 
preoperative GERD and postoperative BOS at either one year (r = -.09,p = .41) or two 
years (r = .02,p = .83) post-transplant. (See Figure 4.2) 
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Figure 4.2 
Survival - GERD - 80S 
100 Lung Transplant Recipients 
~ survival l2l GERD D 80S 
1 month 12months 24months 
GERD and BOS Comparison from ]month to 2 years 
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Research Question Four 
The fourth research question was: What is the sensitivity and specificity of pre-
transplant GERD as a predictor of post-transplant BOS among lung transplant recipients? 
At year one the sensitivity was 36% and the specificity was 51% of pre-transplant GERD 
as a predictor of post-transplant BOS in lung transplant recipients. At year two the 
sensitivity was 58% and the specificity was 50%. 
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CHAPTER FIVE 
Discussion 
This study was a retrospective chart review to evaluate the relationship between 
pre-transplant GERD and the development of post-transplant BOS among lung transplant 
recipients. The records of 100 of patients who received a lung transplant between June 
2001 to October 2005 were reviewed. 
The survival rate for lung transplant recipients was 84% at one year, 74% at two 
years and 63% at three years. This is comparable to national average of78% at one year, 
and 63% at three years for the period January 1994 to June 2006 (Christie et al., 2008). 
The incidence of pre-transplant GERD was 39% in this sample, 61.53% ofwhom 
were male. The overall incidence of GERD in the United States is five per thousand 
(Kahrilas, 2006). Among those awaiting lung transplant the reported incidence is up to 
70% (Benden et al., 2005; Hadjiliadis et al., 2003). 
The incidence of post transplant BOS was 16.67% for the first year and 32.43% in 
the second year in this sample, with 64.28% in the first year and 54.16% in the second 
year being female. This incidence is somewhat lower than that reported in the US as a 
whole where the overall incidence ofBOS is 33.70% (Christie et al., 2008). Among those 
receiving lung transplants the reported incidence is 27% at 2.5 years and 51% at 5.6 years 
(Christie et al., 2008). Blondeau et al. (2008) found similar results in their study off of 
proton pump inhibitors resulting in 63.63% of patients having BOS grade 1 or greater. 
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The relationship between pre-transplant GERD and post transplant BOS was 
35.89% at one year and 61.53% at the second year in this sample. The hypothesis that 
there is a relationship has been validated in many studies who have examined the 
relationship between pre-transplant GERD and post transplant BOS (Benden et al., 2005; 
Blondeau et al., 2009; Blondeau et al., 2008; D'Ovidio & Keshavjee, 2006; D'Ovidio et 
al., 2006; D'Ovidio et al., 2005; Hadjiliadis et al., 2003; Hartwig et al., 2006; Li et al., 
2008; Meltzer et al., 2008; Palmer et al., 2000; Young, Hadjiliadis, Davis, & Palmer, 
2003). 
The sensitivity and specificity of pre-transplant GERD as a predictor of post-
transplant BOS in this study was 36% and 51% at one year and 58% and 50% at two 
years respectively. Sweet et al. (2006) examined the utility of symptomatic screening and 
found the sensitivity and specificity of distal reflux to be 67% and 26% and proximal 
reflux to be 62% and 26% respectively. 
Limitations of the Study 
The fact that these data were all obtained from one facility is a limiting factor to the 
generalizability of the results. The sample size should have been more than adequate to 
find a relationship between pre-transplant GERD and post-transplant BOS (power 
analysis indicated a desired n of 88 and there were 100 in this sample). This, however, 
was not the case, and is contrary to reports of an association found in an animal studies 
(Hartwig et al., 2006; Meltzer et al., 2008) and several other preliminary studies in 
humans (Benden et al., 2005; Blondeau et al., 2009; Blondeau et al., 2008; D'Ovidio et 
al., 2006; D'Ovidio et al., 2005; Hadjiliadis et al., 2003). 
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The retrospective nature of the data collection proved to be a limiting element, 
especially with respect to the diagnosis of pre-transplant GERD. Given the discrepancy 
between the incidence of pre-transplant GERD in this study (39%) and other reports of up 
to 63% (D'Ovidio et al., 2005), it is possible that GERD was underdiagnosed in this 
sample, since the pre-transplant diagnosis was made by a variety of mechanisms, 
including clinical judgment with or without specific testing. Unless the clinician was 
specifically looking for GERD, it may have been missed. When using retrospective data, 
one is also hampered by having to rely on what was previously documented in the 
medical record. 
Future Research 
Prospective studies that include screening for GERD in all patients awaiting 
transplant would add to the evidence that has already been generated. When designing 
these studies, the vulnerable state of the pre-transplant patient should be taken into 
consideration, since the patient may not be strong enough to endure the testing of a pH 
probe or EGD to make a definitive GERD diagnosis. Use of a validated, self-
administered questionnaire such as the Reflux Disease Questionnaire (Shaw et al., 2001) 
might be a useful tool, with anyone scoring positively on the tool treated presumptively 
forGERD. 
Since persons with GERD may be totally asymptomatic, studies might also be 
designed to investigate both clinically symptomatic and asymptomatic GERD and its 
relationship with the development ofBOS post-transplant. Additionally, with the 
presumed relationship between pre-transplant GERD and post-transplant BOS, a study 
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investigating prophylactic treatment for GERD in all patients awaiting lung transplant is 
also warranted. 
Advance Nursing Practice Implications 
Knowledge regarding GERD and BOS gained from this study and others can guide 
the advanced practice nurse in the primary care of lung transplant recipients, allowing for 
identification of the conditions in their early phases of disease. This may have a positive 
impact on lung transplant outcomes. In the pre-transplant period this would include 
helping patients become aware of what Newman (2000) calls evolving patterns, those 
symptoms that may indicate GERD: pyrosis, regurgitation, dysphagia, chest pain, 
hypersalivation, globus sensation, odynophagia, and nausea. The Reflux Disease 
Questionnaire (Shaw et al., 2001) described above could be used to identify the patterns 
and make a presumptive diagnosis. Identification of the pattern could then be followed, 
as appropriate, by testing to make a definitive diagnosis by EGD, espophageal pH 
monitoring, esophageal manometry, barium swallow, and response to antisecretory 
therapy. 
Once the diagnosis is made, either presumptively or through specific testing, 
patient teaching would include avoiding foods that exacerbate symptoms, avoid lying 
down for two to three hours after eating, stop smoking, lose weight, eat smaller and more 
frequent meals, and elevate the head of the bed by six inches. Given the albeit moderate 
association between pre-transplant GERD and post-transplant BOS, appropriate 
pharmacologic management using antisecretory therapy such as H2 blockers, proton 
pump inhibitors should be strongly considered in both preoperative and postoperative 
periods. 
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In the post-transplant period, helping patients understand patterns related to post-
transplant worsening ofGERD and/or the development ofBOS would be important. 
Patient education should include symptoms of worsening GERD, pyrosis, regurgitation, 
or dysphagia or beginning BOS, non productive cough, dyspnea at rest or on exertion, or 
a decrease in FEV 1 readings. Additionally, patients should be assisted to modify or 
eliminate patterns that increase the likelihood of the development of BOS, such as 
preventing episodes of acute rejection, cytomegalovirus pneumonitis, noncompliance 
with immunosuppressive medications and the occurrence of primary graft dysfunction. 
In the ways described above, the APN in primary care can effectively compliment 
any lung transplant team. The addition of an APN to the lung transplant team should also 
be considered, as this individual can be a valuable as part of the transplant team, utilizing 
broad nursing and medically-based education to facilitate comprehensive patient 
management for this population. This could enhance all aspects of lung transplant care 
through the coordination of multidisciplinary efforts and communication among team 
members. 
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Appendix: Data Collection Tool 
Subject TxDate Death Date Survival Alive CurrentAge AgeatTx Sex ABO. 
Subject TxDx1 TxType DateEgd PreTxEgd 'EGO+/- DateEgd PostTxEgd· ·.EGO+/-.·. 
Subject Date Bravo PreTxBravo Bravo+/- Date Bravo PostTxBravo Bravo+/- DatepHProbe 
Subject Pre TxpH Probe Probe+/- DatepHProbe PostTxpHProbe Probe+/- Da'teBaSw 
Subject PreTxBaSw Ba+/- DateBaSw PostTxBaSw Ba+/~ DateDx PreCiinicaiDx Medication 
Subject TxDate Date BOS1Yr BOS1YrGrade Date BOS2Yr BOS2YrGrade 
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